Association Between Frailty & History of Falls in People with MS
“Falls are a major health concern for people with MS, as more than 50% of individuals living with...
Read More
MS
Blacks With MS Are Significantly at Risk for Cardiometabolic Conditions
“MS has long been believed to be more prevalent among White people than Black people, but recent...
Read More
Don’t Assume MS Causes All Changes in Patients’ Disability
As the average age of people with multiple sclerosis (MS) increases, it becomes even more critical...
Read More
Disability Changes in Older Patients with MS May Not be MS-Related
As the average age of people with multiple sclerosis (MS) increases, it becomes even more critical...
Read More
Lesion State Modulates Link Between sNfL & Age in Multiple Sclerosis
Prior research has shown that levels of serum neurofilament light (sNfL), a promising biomarker of...
Read More
A short-term exercise program in patients with multiple sclerosis: is body mass index important?
Obesity is a health problem that can exacerbate the symptoms of multiple sclerosis (MS). In the...
Read More
Don’t Assume MS Causes All Changes in Patients’ Disability
As the average age of people with multiple sclerosis (MS) increases, it becomes even more critical...
Read More
ACTRIMS-ECTRIMS: Ofatumumab Shows Efficacy in New MS Patients
Once-monthly injections allows patients to control their treatment schedule In a group of...
Read MoreACTRIMS-ECTRIMS: Phase 3 EXCHANGE, Insights From Lead Investigator
The interim analysis of the EXCHANGE trial suggest that, for patients with relapsing multiple sclerosis, immediate conversion from oral/injectable disease modifying therapies to siponimod without any washout period (within 24...
Read MoreECTRIMS 2020 Encore Event: NG-Specific Biomarkers Can Quickly Differentiate NMOSD from MS
Neutrophil granulocyte (NG)-specific biomarkers have high sensitivity and specificity for rapid differentiation between acute neuromyelitis optica spectrum disorders (NMOSD), anti-MOG-antibody associated disease (MOGAD), and...
Read MoreECTRIMS 2020 Encore Event: Interrupting DMT Due to Pregnancy Increases NfL Levels in MS
During pregnancy and the disease-modifying treatment (DMT)-free postpartum period, serum neurofilament-light (sNfL) levels were augmented [1]. This increase was independent of relapses, suggesting increased subclinical disease...
Read MoreECTRIMS 2020 Encore Event: Brain Alterations at Onset of First Demyelinating Event
Neurite orientation dispersion and density imaging (NODDI) can detect brain microstructural and metabolic alterations after the first demyelinating event in MS [1]. There was increased axonal dispersion in normal-appearing white...
Read MoreECTRIMS 2020 Encore Event: MS Patients Have No Increased Risk of Contracting COVID-19
People with MS are not more susceptible to COVID-19 infection than the UK general population, suggest results of the largest community-based study of COVID-19 in people with MS worldwide [1]. During lockdown, with strict...
Read MoreFunctional Potential of Gut Microbiome in Pediatric MS
No overall differences in the functional diversity of the gut microbiome were found in patients with pediatric-onset MS in a study using metagenomic sequencing. However, there were differences in the functional potential...
Read MoreGold Nanocrystals May Improve Brain Metabolic Profile
Interim results from two phase 2 studies provide evidence that orally delivered CNM-Au8 (gold nanocrystals) have catalytic effects on key bioenergetic metabolites in the brain of patients with MS and Parkinson’s disease...
Read MoreCardiovascular Risk Factors Linked to Brain Atrophy in Younger MS Patients
The presence of cardiovascular (CV) risk factors is associated with brain atrophy in relatively young MS patients under the age of 50. CV risk factors seem to have synergistic effects in MS. CV risk factors have been associated...
Read MoreEculizumab Reduces Long-Term Relapse Risk in AQP4+ NMOSD
Long-term efficacy and safety results of eculizumab monotherapy in patients with aquaporin-4 IgG-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD) during the PREVENT trial and/or its ongoing open-label extension...
Read MoreGender-based Approach to MS Therapeutics: A Missed Opportunity
Most pivotal disease-modifying treatment (DMT) trials miss an opportunity to evaluate and understand sex differences. There seem to be unexplored sources of bias in observational and interventional studies. Greater attention is...
Read MoreMasitinib Possible New Treatment of Progressive MS
Masitinib is a first-in-class tyrosine kinase inhibitor targeting the innate immune system. Results from a randomised trial with innovative design features indicated it may present a new treatment option for primary progressive...
Read MorePredictive Value of Neurodegenerative CSF Markers in MS
Cerebrospinal fluid (CSF) tau and beta-amyloid (Aβ) proteins are among the biomarkers currently applied in other neurodegenerative diseases than MS. Partly due to conflicting results, not a single biomarker of axonal damage in...
Read More- 1
- 2